NPW1 Stock Chart & Stats
CHF12.29
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF11.53 - CHF12.32
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
CHF9.76B
Enterprise ValueCHF12.08K
Total Cash (Recent Filing)CHF757.91M
Total Debt (Recent Filing)CHF3.80B
Price to Earnings (P/E)19.3
Beta-0.41
Next Earnings
Feb 23, 2027EPS Estimate
0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.76
Shares Outstanding837,417,100
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF14.39Price Target Upside― Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)0.01
Revenue Forecast (FY)CHF71.41M
Bulls Say, Bears Say
Bulls Say
Margin Expansion And Efficiency GainsHigher margins and efficiency savings indicate improving operating discipline. The upgraded 2026 savings target and savings delivered ahead of schedule can support sustained profitability and help offset slower revenue growth.
Sports Medicine Growth And InnovationStrong Sports Medicine performance and continued product launches broaden the company’s growth engines beyond weaker orthopaedics areas. Innovation and procedure-enabling products can deepen surgeon adoption and support recurring consumable demand.
Improved Cash Generation And Manageable LeverageImproving operating and free cash flow strengthens funding capacity for product development, acquisitions and shareholder returns. Leverage remains within management’s stated target, preserving financial flexibility despite ongoing investment.
Bears Say
Lower Revenue Outlook And Reimbursement FrictionThe guidance reduction signals that reimbursement changes and prior authorization processes are creating more persistent barriers to demand. These issues may delay recovery in wound care and orthopaedics and constrain near-term organic growth.
Orthopaedics Portfolio And Deployment WeaknessWeak U.S. knees performance reflects portfolio gaps, while delayed instrument-set deployments restrict hip growth. Sustained underperformance in the largest segment could limit group growth and require continued investment to restore competitiveness.
Chief Financial Officer TransitionA CFO departure introduces leadership and execution risk during a period of restructuring, acquisitions and cash-flow management. An interim arrangement may slow decision-making or create uncertainty around financial controls and capital allocation until a successor is appointed.
NPW1 FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest stock price was CHF11.53 and its highest was CHF12.32 in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is CHF9.76B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Feb 23, 2027 which is in 186 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Aug 04, 2026. The company reported CHF0.385 earnings per share for the quarter, beating the consensus estimate of CHF0.383 by CHF0.002.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc does not currently pay dividends.
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 0.49.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 837,417,100 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of CHF0.385 in its last earnings report, beating expectations of CHF0.383. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in CH:NPW1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF14.39 (― Upside)
CHF14.39 (― Upside)
Insider Transactions
Sold Shares
Worth CHF404.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.41%
12-Months-Change
Fundamentals
Return on Equity
2.57%
Trailing 12-Months
Asset Growth
6.35%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
NPW1 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
Hikma Pharmaceuticals
―
PureTech Health
―
Spire Healthcare
―









